210240-20-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Aminotetrahydro-2H-thiopyran 1,1-dioxide is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the creation of new drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Aminotetrahydro-2H-thiopyran 1,1-dioxide serves as a precursor for the development of new agrochemicals, contributing to the advancement of crop protection and management solutions.
Used in Organic Synthesis:
4-Aminotetrahydro-2H-thiopyran 1,1-dioxide is employed as a versatile building block in organic synthesis, enabling the construction of a wide array of chemical compounds with diverse applications.
Used in Anti-Inflammatory Research:
4-Aminotetrahydro-2H-thiopyran 1,1-dioxide is explored for its potential as an anti-inflammatory agent, with studies focusing on its capacity to modulate inflammatory pathways and provide therapeutic benefits in treating inflammation-related conditions.
Used in Anti-Cancer Research:
4-Aminotetrahydro-2H-thiopyran 1,1-dioxide is investigated for its potential role in anti-cancer research, where it may contribute to the development of novel cancer treatments by targeting specific cancer cell mechanisms or enhancing the effectiveness of existing therapies.

InChI:InChI=1/C5H11NO2S/c6-5-1-3-9(7,8)4-2-5/h5H,1-4,6H2

Upstream product

• 887978-12-3 N-benzyl-1,1-dioxotetrahydro-2H-thiopyran-4-amine 
• 1072-72-6 Tetrahydrothiopyran-4-one 
• 21926-00-1 4-tetrahydrothiopyranylamine 
• 6309-59-7 tetrahydro-4H-thiopyran-4-one oxime 
• 402927-99-5 N-benzoyloxycarbonylsulfone 
• 17396-35-9 1,1-dioxotetrahydrothiopyran-4-one 
• 595597-01-6 1,1-dimethylethyl (1,1-dioxidotetrahydro-2H-thiopyran-4-yl)carbamate 
• 99586-63-7 1,1-dioxo-tetrahydro-1λ⁶-thiopyran-4-one oxime 

Downstream Products

• 863438-78-2 N-(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)-7-[(4-fluorophenyl)methyl]-4-hydroxy-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide 
• 1089669-66-8 5-[2-(difluoromethyl)-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2-thiophenesulfonamide 
• 1410737-37-9 (3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-N-(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)-2''-oxodispiro-[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide 
• 1621272-04-5 (R)-4-(4-cyanophenyl)-2,5-dioxo-N-(1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-yl)-1-(3-(trifluoromethyl)phenyl)-4,5,6,7-tetrahydro-1H-cyclopenta[d]pyrimidine-3(2H)-carboxamide 
• 1552306-83-8 C₁₉H₂₅N₃O₅S 
• 1279093-54-7 C₁₂H₁₂BrFN₂O₂S 
• 1279091-35-8 C₂₆H₂₈FN₃O₄S 
• 1279093-55-8 C₁₂H₁₄BrFN₂O₃S 

Relevant academic research and scientific papers

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

1-(DIHYDRONAPHTHALENYL)PYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS

Provided are 1-(dihydronaphthalenyl)pyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy for the treatment of obesity and diabetes.

Kinase inhibitor compounds

The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

SOLUBLE EPOXIDE HYDROLASE INHIBITORS

Disclosed are amide, thioamide, urea and thiourea compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, and diabetic-related diseases.

2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel Anilinopiperazine Derivatives of formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.

KINASE INHIBITOR COMPOUNDS

The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of kinase-mediated processes, and treatment of disease and disease symptoms, particularly those mediated by certain kinase enzymes.

Imidazo-substituted compounds as p38 kinase inhibitors

The present invention discloses compounds corresponding to formula I: wherein A, Z, Z1, Y, R1 and R2 are as defined in the specification, as well as pharmaceutical formulations, methods of making and uses thereof.